RT Journal Article
SR Electronic
T1 Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4157
OP 4163
DO 10.21873/anticanres.14415
VO 40
IS 7
A1 MASATSUNE SHIBUTANI
A1 HISASHI NAGAHARA
A1 TATSUNARI FUKUOKA
A1 YASUHITO ISEKI
A1 EN WANG
A1 YUKI OKAZAKI
A1 SHINICHIRO KASHIWAGI
A1 KIYOSHI MAEDA
A1 KOSEI HIRAKAWA
A1 MASAICHI OHIRA
YR 2020
UL http://ar.iiarjournals.org/content/40/7/4157.abstract
AB Background/Aim: The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated. However, little is known about the impact of a usage history of bevacizumab in front-line treatment on the clinical benefit of combining bevacizumab with FTD/TPI. Patients and Methods: A total of 62 patients with mCRC treated with FTD/TPI±bevacizumab was enrolled and assessed for chemotherapeutic efficacy and adverse events. Results: Regardless of the usage history of bevacizumab in front-line treatment, the FTD/TPI plus bevacizumab group had a significantly better progression-free survival rate than the FTD/TPI monotherapy group, and no significant differences in the safety profile were observed between the two groups. Conclusion: Combining bevacizumab with FTD/TPI improves the survival outcomes with manageable toxicity, regardless of the usage history of bevacizumab in front-line treatment, in patients with mCRC.